Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ACE-536 in β-thalassemia patients from A536-04
2014-001281-94Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in beta thalassemia major and beta-thalassemia intermedia, sponsored by Acceleron Pharma Inc. Primary endpoint: Long-term safety and tolerability of ACE-536. Started Jun 2014; status: completed.
02
Drugs
luspatercept
03
Conditions
beta thalassemia majorbeta-thalassemia intermedia
Beyond the preview
Go deeper on 2014-001281-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001281-94.